TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3512080
Drug: mazindol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: mazindol (1 mg)
Study: 27181196
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for 3 months
Study: 20398300
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days moxifloxacin 400 mg/d with amoxycillin 1 g twice daily and lansoprasole 30 mg twice daily
Study: 20398300
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days moxifloxacin 400 mg/d with amoxycillin 1 g twice daily and lansoprasole 30 mg twice daily
Study: 16143734
Drug: Alprazolam 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 1.5 mg/d
Study: 11953922
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.6 g/kg/d)
Study: 7579027
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of reboxetine (2, 3, 4, and 5 mg)
Study: 7579027
Drug: Reboxetine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (4 mg therapeutic tablet formulation)
Study: 7579027
Drug: Reboxetine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (various doses)
Study: 1834808
Drug: Toremifene (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene (10, 20, 40, 60, 200, or 400 mg/d orally) for at least 8 weeks
Study: 6772047
Drug: Dihydrazinophthalazine (Nepresol)
Normalized name: Dihydrazinophthalazine
DrugBank: Dihydralazine (DB12945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrazinophthalazine (Nepresol) 45 +/- 12 mg
Study: 30337189
Drug: Weaning at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weaning at 1600 g
Study: 28506538
Drug: Nexvax2 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nexvax2 60 μg
Study: 28506538
Drug: Nexvax2 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nexvax2 90 μg
Study: 28506538
Drug: Nexvax2 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nexvax2 150 μg
Study: 28506538
Drug: Nexvax2 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nexvax2 150 μg (biopsy cohort)
Study: 28506538
Drug: Nexvax2 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nexvax2 300 μg
Study: 28506538
Drug: Nexvax2 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nexvax2 150 μg (MTD)
Study: 26482674
Drug: HPV vaccine-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine-specific brochure, telephone recalls to parents who declined, and recalls to patients overdue for doses 2 and 3
Study: 26482674
Drug: General adolescent
Approvals — FDA: no, EMA: no, PMDA: no
Description: General adolescent vaccine brochure (active comparison)
Study: 24429154
Drug: Nebulised MgSO(4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised MgSO(4) (three 500 mg doses in 1 h) alongside standard therapy
Study: 24429154
Drug: Intravenous MgSO(4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous MgSO(4) (2 g in 20 min) alongside standard therapy
Study: 24429154
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control plus standard therapy alone
Study: 19953707
Drug: Lanreotide 30
Normalized name: lanreotide 300 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide 30 mg PR
Study: 3727190
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor training program (5 weekly lessons guided by trained physiotherapists)
Study: 30689800
Drug: Reduced ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced ticagrelor maintenance dose (60 mg b.i.d)
Study: 30689800
Drug: Standard ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard ticagrelor maintenance dose (90 mg b.i.d)
Study: 22545007
Drug: Monthly magazines
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly magazines and newsletters aimed at promotion of healthy eating
Study: 20832366
Drug: fixed‐dose artesunate‐mefloquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: fixed‐dose artesunate‐mefloquine
Study: 20832366
Drug: primaquine (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: primaquine (0.75 mg/kg)
Study: 2019665
Drug: Epinephrine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (0.2 mg/inh) followed by theophylline (130 mg) with ephedrine (24 mg)
Study: 2019665
Drug: Metaproterenol (0.65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol (0.65 mg/inh)
Study: 2019665
Drug: Placebo inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhaler and tablets
Study: 7056196
Drug: human milk
Normalized name: HUMAN MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: human milk (1.6 g/100 kcal)
Study: 7056196
Drug: formula 1
Normalized name: Abena Man Formula 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: formula 1 (2.3 g/100 kcal)
Study: 7056196
Drug: formula 2
Normalized name: Formula 21
Approvals — FDA: no, EMA: no, PMDA: no
Description: formula 2 (3.0 g/100 kcal)
Study: 7056196
Drug: formula (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: formula (1.6 g/100 kcal, 2.3 g/100 kcal, 3.0 g/100 kcal)
Study: 25185149
Drug: Pulmonary rehabilitation
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary rehabilitation program (3 months, twice-weekly, 90-min exercise sessions, total 24 sessions)
Study: 20137596
Drug: Intravenous flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous flurbiprofen 100 mg before surgery (Group A)
Study: 20137596
Drug: Intravenous flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous flurbiprofen 100 mg at the end of surgery (Group C)
Study: 16685553
Drug: 48-week strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48-week strength training, performed twice per week, consisting of three series of 10 repetitions of calf-rise at 75% of the 3-repetition maximum.
Study: 16019074
Drug: No initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No initial treatment
Study: 12136369
Drug: Tezosentan (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan (6.25 mg/h and 25 mg/h for 6 h) with cyclosporin (400 mg single dose)
Study: 12136369
Drug: Tezosentan (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan (6.25 mg/h and 25 mg/h for 6 h) alone
Study: 10597779
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ZDV-ddC, ZDV-ddI, D4T-ddI, three-drug regimen)
Study: 10597779
Drug: Three-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug regimen (stavudine, lamivudine, ritonavir)
Study: 10597779
Drug: Two-drug groups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug groups
Study: 1957876
Drug: Oral communication
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral communication channel
Study: 7036281
Drug: LMF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMF plus BCG (greater than 90% of planned LMF dose)
Study: 22562783
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of moxifloxacin 0.5%/dexamethasone 0.1% ophthalmic solution
Study: 22562783
Drug: Moxifloxacin 0.5%
Normalized name: Moxifloxacin 0.5%, Bromfenac 0.075% Ophthalmic drops, solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 0.5% ophthalmic solution and dexamethasone 0.1% (concomitant group)
Study: 14641923
Drug: Trimetazidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (20 mg, t.d.s.)
Study: 10965102
Drug: Ondansentron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansentron 8 mg every 8 hours with dexamethasone 8 mg before cisplatin infusion and continued after 8 and 16 hours.
Study: 10965102
Drug: Ondansentron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansentron 8 mg every 6 hours with dexamethasone 8 mg before cisplatin infusion and continued after 6, 12, and 18 hours.
Study: 10965102
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received a total dose of 24 mg ondansentron during the acute phase of emesis.
Study: 1795315
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mineral baths and mud packs (Group 1)
Study: 6225751
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg bw
Study: 6225751
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg bw
Study: 6225751
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg bw
Study: 25619045
Drug: Intra-articular sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular sodium hyaluronate (1%; 2,2-2,7 MDa), administered once weekly for 3 weeks (3 injections)
Study: 25619045
Drug: Symptomatic slow-acting
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic slow-acting drugs for osteoarthritis (SYSADOA)
Study: 22349603
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) at 6 weeks after surgery
Study: 17668086
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide bleaching agents (3M Zaris, 3M Espe; Nite White Excel, Discus Dental)
Study: 11493236
Drug: Alfentanil-morphine mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil-morphine mixture (0.75 : 10 mg)
Study: 9808867
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A levels > 3 mg/kg/day
Study: 11262334
Drug: HMG-CoA-reductase inhibitors
Normalized name: HMG CoA reductase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG-CoA-reductase inhibitors
Study: 9808867
Drug: Strategies for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strategies for blocking T-cell costimulation and expression of adhesion molecules, cytokines and antiendothelial antibodies, antiproliferative drugs, methods to augment endogenous nitric oxide bioavailability, newer immunosuppressive regimens
Study: 3181646
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (4.0 g omega-3 fatty acids)
Study: 3181646
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (7.5 g omega-3 fatty acids)
Study: 27056846
Drug: MAXout treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAXout treatment (18-week treatment, two 90-minute sessions per week)
Study: 19407804
Drug: Verapamil SR-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil SR-based antihypertensive treatment
Study: 19407804
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (Verapamil and Atenolol)
Study: 15126313
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment to eradicate H pylori infection
Study: 9781431
Drug: Sparfloxacin 200
Normalized name: sparfloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin 200 mg administered 1 hour before urethrocystoscopy
Study: 9781431
Drug: Fleroxacin 200
Normalized name: fleroxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 200 mg administered 1 hour before urethrocystography
Study: 9781431
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic (control group) for both procedures
Study: 3244560
Drug: Caffeine ingestion
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine ingestion (4 mg.kg b.w.‐1)
Study: 22930491
Drug: Mindfulness‐Based Stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness‐Based Stress Reduction (MBSR) plus treatment as usual (TAU)
Study: 18454988
Drug: Early steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early steroid reduction (G1; n = 31)
Study: 18454988
Drug: Regular steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular steroid dosage maintenance (G2; n = 29)
Study: 14728104
Drug: Olanzapine (7.5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (7.5-20 mg/day)
Study: 2914436
Drug: Epiquick patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epiquick patch test on the left side
Study: 2914436
Drug: Epiquick patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epiquick patch test on the right side
Study: 770080
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg azapropazone daily
Study: 770080
Drug: 3.9 g
Normalized name: aspirin 3.9 GM Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.9 g aspirin daily
Study: 28326559
Drug: RG7652 (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7652 (10, 40, 150, 300, 600, or 800 mg single dose)
Study: 28326559
Drug: RG7652 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7652 (40 or 150 mg multiple doses once weekly for 4 weeks)
Study: 28326559
Drug: RG7652 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7652 with atorvastatin
Study: 26490026
Drug: Concurrent chemo-endocrine
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemo-endocrine therapy (goserelin for premenopausal women or an aromatase inhibitor for postmenopausal women)
Study: 26490026
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide)
Study: 23266743
Drug: 6 tablets
Normalized name: ALLANTOIN 66 mg in 600 mg VAGINAL TABLET [Jilgyungyi (6 Tablets)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 tablets of dietary supplement (DS) containing red yeast rice extract, policosanol and artichoke leaf extract
Study: 23266743
Drug: 3 tablets
Normalized name: Xpovio 60 MG Weekly Dose Carton Pack, 4 Blister Cards, 3 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets of dietary supplement (DS) containing red yeast rice extract, policosanol and artichoke leaf extract
Study: 23266743
Drug: 6 tablets
Normalized name: ALLANTOIN 66 mg in 600 mg VAGINAL TABLET [Jilgyungyi (6 Tablets)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 tablets of dietary supplement (DS)
Study: 23266743
Drug: 3 tablets
Normalized name: Xpovio 60 MG Weekly Dose Carton Pack, 4 Blister Cards, 3 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets of dietary supplement (DS)
Study: 23266743
Drug: 6 tablets
Normalized name: ALLANTOIN 66 mg in 600 mg VAGINAL TABLET [Jilgyungyi (6 Tablets)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 tablets of dietary supplement (DS) and 3 tablets of dietary supplement (DS)
Study: 17428714
Drug: Inhaled furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled furosemide (40 or 80 mg)
Study: 10683600
Drug: SPORT (dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPORT (dietary supplement)
Study: 9587555
Drug: 18 patients
Normalized name: onasemnogene abeparvovec
DrugBank: Onasemnogene abeparvovec (DB15528)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18 patients who had a second biopsy 6 months after therapy
Study: 8410127
Drug: 4HPR 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4HPR 200 mg/d for 5 years
Study: 30776254
Drug: Taurine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine (50 mg kg‐1)
Study: 30268158
Drug: Low-frequency electrostimulation
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency electrostimulation (ES) administered via CarebandR wristband on unilateral PC6 acupoint
Study: 26672608
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg elemental iron once weekly (Group-A)
Study: 26672608
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg elemental iron twice weekly (Group-B)
Study: 22890091
Drug: Prulifloxacin 264.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prulifloxacin 264.2 mg b.i.d. for 5-14 days
Study: 22890091
Drug: Levofloxacin 200
Normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 200 mg b.i.d. for 5-14 days
Study: 18946341
Drug: Concentration-controlled MMF
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentration-controlled MMF regimen (target exposure 45 mg hr/L)
Study: 18946341
Drug: Fixed-dose MMF
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose MMF regimen
Study: 16054584
Drug: Amodiaquine +
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amodiaquine + Artesunate (ADQ+ART) combination
Study: 16054584
Drug: Artemether +
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artemether + Lumefantrine (Coartem) combination
Study: 12468602
Drug: Spread enriched
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spread enriched with plant sterol-esters (12 g/100 g plant sterols), intake of 15 g/d
Study: 10522000
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg once daily before breakfast
Study: 10522000
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg once daily at bedtime
Study: 1826987
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (600 mg ascorbic acid, 300 mg alpha‐tocopherol, 27 mg beta‐carotene, and 75 micrograms selenium in yeast daily)
Study: 30685675
Drug: Evolocumab (proprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (proprotein convertase subtilisin‐kexin type 9 inhibitor)
Study: 21893649
Drug: Daily controller
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily controller use (yes)
Study: 21893649
Drug: Leukotriene inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukotriene inhibitors (yes)
Study: 21893649
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (yes)
Study: 15235319
Drug: DCA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCA (50 mg·kg‐1 body mass in 50 mL saline)
Study: 11238496
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg, 3 times daily for 4 weeks)
Study: 11238496
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 times daily for 4 weeks)
Study: 9928576
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment A(doxorubicin)-T(paclitaxel)-C(cyclophosphamide) with G-CSF
Study: 9928576
Drug: AC x
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC x 4 followed by high-dose chemotherapy with stem cell support
Study: 31204870
Drug: Self-administered anonymous
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered anonymous questionnaire regarding fertility management knowledge
Study: 27959700
Drug: Platinum therapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum therapy plus pemetrexed (500 mg/m² + carboplatin AUC5 or cisplatin 75 mg/m² every 3 weeks)
Study: 27959700
Drug: Platinum therapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum therapy plus pemetrexed
Study: 26041765
Drug: Comfort level
Normalized name: Comfort Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comfort level with prescribing treatment to ECOG 4 patients
Study: 21494196
Drug: Real electroacupuncture
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real electroacupuncture treatment
Study: 21494196
Drug: Simulated electroacupuncture
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated electroacupuncture treatment (Control)
Study: 19688181
Drug: Tacrolimus (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (3 mg/day)
Study: 15356433
Drug: Daily needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily needle aspiration
Study: 9133750
Drug: Active treatments
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatments (Imipramine)
Study: 27083332
Drug: Ponatinib (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib (45 mg once daily)
Study: 27083332
Drug: Imatinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (400 mg once daily)
Study: 14760148
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg salbutamol administered through a pMDI+spacer 20 minutes before induction
Study: 14760148
Drug: 1500 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 microg nebulised salbutamol inhaled throughout the induction procedure
Study: 7583013
Drug: Garlic capsules
Normalized name: Garlic 500 MG Oral Capsule, Liquid Filled [GARLIC CAPSULES]
DrugBank: Garlic (DB10532)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic capsules
Study: 2378856
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol maleate (0.5%)
Study: 2378856
Drug: Topical betaxolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betaxolol hydrochloride (0.5%)
Study: 387069
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of micronized 17 beta‐oestradiol and 3 mg norethisterone (Netagen 403)
Study: 387069
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg 17 beta‐oestradiol plus 2 mg of oestriol and 3 mg norethisterone (Netagen 423)
Study: 387069
Drug: 50 microgram
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microgram ethinyl oestradiol and 3 mg norethisterone (Netasyn)
Study: 24147745
Drug: gel without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gel without desensitizing agent (n=17)